Thursday, 25 Apr 2019

You are here

2018 EULAR Recommendations for Hand Osteoarthritis Care

The uropean League Against Rheumatism (EULAR) has previously put forth recommendations for management of hand osteoarthritis (OA) in 2007. But since then, advances and further evidence have emerged.

An international panel of 19 physicians, healthcare professionals and patients from 10 European countries formulated five overarching principles and 10 new recommendations after a systematic literature review was performed.

The overarching principles cover treatment goals, information provision, individualisation of treatment, shared decision-making and the need to consider multidisciplinary and multimodal (non-pharmacological, pharmacological, surgical) treatment approaches.

Recommendations address non-pharmacological treatment options, pharmacological treatments, and surgical considerations.  These EULAR recommendations provide up-to-date guidance on the management of hand OA, based on expert opinion and research evidence.

Overarching Principles

  • The primary goal of managing hand OA is to control symptoms, such as pain and stiffness, and to optimise hand function, in order to maximise activity, participation and quality of life.
  • All patients should be offered information on the nature and course of the disease, as well as education on self-management principles and treatment options.
  • Management of hand OA should be individualised taking into account its localisation and severity, as well as comorbidities.
  • Management of hand OA should be based on a shared decision between the patient and the health professional.
  • Optimal management of hand OA usually requires a multidisciplinary approach. In addition to non-pharmacological modalities, pharmacological options and surgery should be considered.

Recommendations for Hand OA Management

  1. Education and training in ergonomic principles, pacing of activity and use of assistive devices should be offered to every patient.
  2. Exercises to improve function and muscle strength, as well as to reduce pain, should be considered for every patient.
  3. Orthoses should be considered for symptom relief in patients with thumb base OA. Long-term use is advocated.
  4. Topical treatments are preferred over systemic treatments because of safety reasons. Topical NSAIDs are the first pharmacological topical treatment of choice.
  5. Oral analgesics, particularly NSAIDs, should be considered for a limited duration for relief of symptoms.
  6. Chondroitin sulfate may be used in patients with hand OA for pain relief and improvement in functioning.
  7. Intra-articular injections of glucocorticoids should not generally be used in patients with hand OA, but may be considered in patients with painful interphalangeal joints
  8. Patients with hand OA should not be treated with conventional or biological disease-modifying antirheumatic drugs
  9. Surgery should be considered for patients with structural abnormalities when other treatment modalities have not been sufficiently effective in relieving pain. Trapeziectomy should be considered in patients with thumb base OA and arthrodesis or arthroplasty in patients with interphalangeal OA.
  10. Long-term follow-up of patients with hand OA should be adapted to the patient’s individual needs.
Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

NIH Workshop on Unmet Needs in Osteoporosis

In October 2018, the National Institutes of Health (NIH) convened a workshop to address the "Appropriate Use of Drug Therapies for Osteoporotic Fracture Prevention"

Intraarticular Trans-Capsaicin Effective in Knee OA

A novel study has shown that intraarticular therapy with high‐purity synthetic trans‐capsaicin (CNTX‐4975) for chronic knee osteoarthritis (KOA) was associated with significant relief of knee pain.

Smoking Not Protective Against Knee OA

Researchers found no protective effect of smoking against knee osteoarthritis (OA), according to a new longitudinal cohort study of 620 individuals with meniscal tears treated at five sites in Denmark. An inverse association between OA and smoking had been suggested by several previous studies and a recent meta-analysis.  

FDA Approves Romosuzumab (Evenity) for High Risk Osteoporosis

The US Food and Drug Administration today approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of osteoporotic fracture, including those with a history of osteoporotic fracture or multiple risk factors for fracture, or those who have failed or are intolerant to other osteoporosis therapies.

Guidelines for Osteoporosis Management in Postmenopausal Women

New guidelines on the  "Pharmacologic Management of Osteoporosis in Postmenopausal Women," were presented March 25 at ENDO 2019 - The Endocrine Society Annual Meeting and simultaneously published online in the Journal of Clinical Endocrinology & Metabolism.